# Evaluation of FDY-5301 in Major Trauma Patients in ICU

> **NCT04430283** · PHASE2 · TERMINATED · sponsor: **Faraday Pharmaceuticals, Inc.** · enrollment: 8 (actual)

## Conditions studied

- ICU Acquired Weakness

## Interventions

- **DRUG:** FDY-5301
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04430283
- **Lead sponsor:** Faraday Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-20
- **Primary completion:** 2022-03-04
- **Final completion:** 2022-03-04
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The study was terminated because of difficulty identifying patients that met the inclusion criteria, as well as logistical difficulties in opening clinical ICU study sites.
- **Last updated:** 2023-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04430283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04430283, "Evaluation of FDY-5301 in Major Trauma Patients in ICU". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04430283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*